Orchestra BioMed Holdings, Inc.
OBIO
$2.78
$0.207.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -3.44% | 135.56% | -14.97% | -46.74% | -76.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.44% | 135.56% | -14.97% | -46.74% | -76.25% |
| Cost of Revenue | 23.40% | 65.85% | -18.52% | -22.73% | -11.32% |
| Gross Profit | -9.30% | 143.12% | -14.75% | -47.68% | -79.52% |
| SG&A Expenses | 41.00% | -10.69% | 21.61% | 33.69% | 25.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.86% | 15.97% | 27.15% | 18.36% | 16.58% |
| Operating Income | -33.62% | -12.52% | -30.13% | -24.93% | -26.99% |
| Income Before Tax | -26.03% | -15.85% | -32.66% | -23.06% | -31.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.03% | -15.85% | -32.66% | -23.06% | -31.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.03% | -15.85% | -32.66% | -23.06% | -31.47% |
| EBIT | -33.62% | -12.52% | -30.13% | -24.93% | -26.99% |
| EBITDA | -33.72% | -12.54% | -30.29% | -25.06% | -27.17% |
| EPS Basic | -16.34% | -8.52% | -28.28% | 4.93% | 24.25% |
| Normalized Basic EPS | -31.14% | -6.22% | -28.45% | 5.37% | 31.63% |
| EPS Diluted | -16.34% | -8.52% | -28.28% | 4.93% | 24.25% |
| Normalized Diluted EPS | -31.14% | -6.22% | -28.45% | 5.37% | 31.63% |
| Average Basic Shares Outstanding | 8.32% | 6.75% | 3.43% | 29.43% | 73.58% |
| Average Diluted Shares Outstanding | 8.32% | 6.75% | 3.43% | 29.43% | 73.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |